Kairos Pharma, Ltd. (简称：Kairos Pharma) 正式宣布，已签署一项具有约束力的战略资产收购协议。根据协议，Kairos Pharma将获得来自Orbimed及Torrey Pines投资支持的Celyn Therapeutics所持有的Cl-273项目的全球独家权利。
此次收购标志着Kairos Pharma在拓展其产品管线方面迈出关键一步，进一步巩固了公司在创新疗法领域的战略布局。Cl-273作为一项具有潜力的候选药物，其全球独家权利的获取将为公司未来业务增长注入新动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.